Mumbai – BDR Pharmaceuticals International Private Limited, a pioneering pharmaceutical company, is proud to announce the launch of Dalbonova Injection. A revolutionary medication for the treatment of acute bacterial skin and skin structure infections caused by designated susceptible strains of Gram-positive microorganisms. This ground breaking drug will be available as a 500 mg injection and marks an important milestone in the field of anti-infective medicines in India.

According to the latest data from the World Health Organization (WHO), in 2023 there were an estimated 11.5 million cases of Acute bacterial skin and skin structure infections (ABSSSI) in India. This represents a 15% increase in the number of cases from 2022. The male-to-female ratio for ABSSSI in India is 1.2:1. This means that men are about 20% more likely to develop ABSSSI than women. Children under the age of five and people over the age of 65 throughout India have the highest incidence of ABSSSI. The incidence of ABSSSI varies by area in India as well, with Gujarat, Rajasthan, and Uttar Pradesh, to mention a few, having the highest rates. Certain population groups in India, such as those with diabetes, HIV/AIDS, and poverty, bear a disproportionately high burden of ABSSSI.

Dalbonova revolutionizes medical treatment with its single-dose therapy for acute bacterial skin and skin structure infections (ABSSSI) in patients of all ages, including newborns. This innovative approach simplifies treatment, eliminates the need for hospital admissions, and reduces the risk of hospital-acquired infections. Unlike traditional methods involving multiple infusions over days, Dalbonova’s dosing regimen offers remarkable convenience and effectiveness. Patients can opt for a potent single-dose of 1500 mg or a comprehensive two-dose regimen of 1000 mg followed by 500 mg after one week, catering to individual needs.

While commenting on the new launch, Mr. Raheel Shah, Director of BDR Pharmaceuticals said, Dalbonova Injection is set to provide significant benefits to adult and pediatric patients suffering from ABSSSI. With its innovative approach, BDR Pharmaceuticals aims to enhance patient care and accessibility while making the treatment more affordable for Indian patients. This advanced treatment will not only save valuable time but also reduce the overall cost burden associated with traditional treatment approaches.

After Looking at the situation in India this condition was affecting a high number of individuals. BDR Pharma remains determined to improve patient lives and advance cutting-edge treatments with the introduction of Dalbonova Injection, the company strives to provide a game-changing solution for individuals battling Acute bacterial skin and skin structure infections (ABSSSI). India is ensuring that patients receive the finest care possible by funding cutting-edge research, encouraging partnerships, and consistently enhancing the nation’s medical infrastructure. It is also significantly time and cost savings. With this BDR aims to introduce innovative medicines first time in India in Anti-Infective segment and also make them affordable for Indian patients.